Ginkgo Bioworks Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands except share data)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedDeficit | AccumulatedOtherComprehensive(Loss) Income | TotalStockholders’Equity | |
| Balance as of December 31, 2022 | 47,299,399 | $5 | $6,136,563 | $(4,397,659) | $(2,632) | $1,736,277 |
| Issuance of common stock upon exercise or vesting of equity awards | 2,469,178 | — | 555 | — | — | 555 |
| Tax withholdings related to net share settlement of equity awards | (360) | — | (23) | — | — | (23) |
| Settlement of contingent consideration | 96,198 | — | 8,896 | — | — | 8,896 |
| Issuance of common stock for asset acquisitions | 119,278 | — | 6,820 | — | — | 6,820 |
| Issuance of common stock in exchange for services | 50,587 | — | 2,500 | — | — | 2,500 |
| Forfeiture of restricted stock | (1,407) | — | — | — | — | — |
| Stock-based compensation expense and other | — | — | 230,880 | — | — | 230,880 |
| Foreign currency translation | — | — | — | — | 4,116 | 4,116 |
| Net loss | — | — | — | (892,869) | — | (892,869) |
| Balance as of December 31, 2023 | 50,032,873 | 5 | 6,386,191 | (5,290,528) | 1,484 | 1,097,152 |
| Issuance of common stock upon exercise or vesting of equity awards | 1,783,763 | — | 543 | — | — | 543 |
| Payment for fractional shares after reverse stock split | — | — | (4) | — | — | (4) |
| Settlement of contingent consideration | 1,385,532 | — | 14,742 | — | — | 14,742 |
| Issuance of common stock for asset acquisitions | 802,038 | — | 36,801 | — | — | 36,801 |
| Issuance of common stock in exchange for services | 361,579 | — | 4,799 | — | — | 4,799 |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | — | — | — | — | 1,492 | 1,492 |
| Stock-based compensation expense | — | — | 112,344 | — | — | 112,344 |
| Foreign currency translation | — | — | — | — | (4,782) | (4,782) |
| Net loss | — | — | — | (547,029) | — | (547,029) |
| Balance as of December 31, 2024 | 54,365,785 | 5 | 6,555,416 | (5,837,557) | (1,806) | 716,058 |
| Issuance of common stock upon exercise or vesting of equity awards | 1,798,041 | — | — | — | — | — |
| Issuance of common stock in ATM offering, net of $(1,393) issuance costs | 1,940,550 | — | 18,078 | — | — | 18,078 |
| Release of 24,913 common shares from escrow related to acquisition | — | — | 1,237 | — | — | 1,237 |
| Issuance of common stock in settlement of purchase price holdback | 102,922 | 1 | 776 | — | — | 777 |
Consolidated Statements of Stockholders’ Equity
(in thousands except share data)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedDeficit | AccumulatedOtherComprehensive(Loss) Income | TotalStockholders’Equity | |
| Stock-based compensation expense | — | — | 81,546 | — | — | 81,546 |
| Other comprehensive income | — | — | — | — | 3,657 | 3,657 |
| Net loss | — | — | — | (312,763) | — | (312,763) |
| Balance as of December 31, 2025 | 58,207,298 | $6 | $6,657,053 | $(6,150,320) | $1,851 | $508,590 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.